Other · developed by Novartis Pharmaceuticals
DDY391 is a drug studied in rheumatoid arthritis. The available source text does not describe its molecular class, target or mechanism of action.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07951086 | Phase 2 | Rheumatoid Arthritis | Not yet recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Rheumatoid Arthritis
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →